|

Novo Nordisk Rebrands as ‘Novo’: Stock Falls as Company Aims GLP-1s at Consumers

Novo Nordisk (NVO) rebranded itself as merely “Novo” on Monday, unveiling a brand new company tradition framework as the Danish drugmaker tries to shut a widening hole with rival Eli Lilly within the weight problems drug market.

CEO Mike Doustdar instructed CNBC the rebrand and tradition shift are a part of the identical package deal for evolving the corporate’s technique.

Strategy Behind the Shift

Doustdar said the corporate’s working atmosphere modified as weight problems therapy shifted from a secure, insulin-like market to at least one that behaves extra like a shopper market, the place sufferers cycle on and off medicine.

The new tradition, dubbed “The Novo Way,” is constructed on 4 ideas. Those are buyer obsession, competitiveness, readability, and care and integrity. Doustdar mentioned pace solely helps as soon as priorities are clear, including the corporate nonetheless has work to do throughout analysis, manufacturing, and gross sales.

The rebrand additionally reverses the path of Novo’s centuries-old Apis bull emblem, a symbolic nod to altering course whereas retaining its heritage. Novo Nordisk A/S stays the corporate’s authorized title.

Stock Reaction

Investors weren’t too taken with the information. Novo shares traded round $43.45 on Monday, down about 15.8% year-to-date and off roughly 21% over the previous 12 months. The inventory has fallen greater than 60% from its 2024 peak close to $147, when Novo led the GLP-1 race.

The inventory has ticked up barely since Monday, however shares are usually down. Image Source: Trading View

Analysts at BMO famous that the robust launch of Novo’s oral Wegovy tablet this 12 months doesn’t by itself sign a turnaround. Doustdar pointed to early Medicare uptake amongst weight problems sufferers as an encouraging, if nonetheless early, sign for demand.

“The road and the market is at all times proper, however with a lag.”

— Mike Doustdar, CNBC

He mentioned continued execution ought to ultimately restore investor belief. Novo continues to work to defend its lead over Eli Lilly’s competing oral tablet.

The put up Novo Nordisk Rebrands as ‘Novo’: Stock Falls as Company Aims GLP-1s at Consumers appeared first on BeInCrypto.

Similar Posts